Browse Data and Analysis

On November 21, 2020, Canada announced conclusion of an interim trade agreement to mitigate possible trade disruption associated with the United Kingdom leaving the European Union...

Latin America accounts for about 25 percent of global corn imports . The region’s corn demand for imported corn has grown steadily over the years supported by expansion in the livestock sector...

Bilateral trade of agricultural products between the United States and the Dominican Republic has increased during the first six months of Calendar Year 2020 (CY 2020), despite the COVID-19 pandemic.

Australia reached a partial settlement with Canada on its World Trade Organization dispute over Canadian federal and provincial wine measures.

The United States-Mexico-Canada Agreement (USMCA) came into effect July 1, 2020. Under the agreement, Canada agrees to allow grain grown in the United States to receive an official Canadian grade...

Infographic looking at the agricultural trade between the U.S., Mexico and Canada. The U.S. exported nearly $40 billion in agriculture to these two countries in 2018.

A more flexible certification of origin process under the United States-Mexico-Canada Agreement will take effect when the agreement enters into force on July 1, 2020.

After several years of negotiations, on April 28, 2020, FAS/Brasilia received an official response from the Ministry of Agriculture, Livestock, and Food Supply (MAPA), approving the final language...

The Government of Mexico (GOM) is creating uncertainty about the future acceptance of biotechnology and genetically engineered (GE) crops in Mexico.

Ecuador extended its tariff exemption for soybean meal and wheat imports from all origins for five years, effective January 1, 2020.

Global Affairs Canada published policy options for the allocation and administration rules for all tariff rate quotas (TRQs) related to supply-managed products (i.e., dairy, poultry and eggs).

Health Canada has provided an update on the re-evaluation of three neonicotinoids (imidacloprid, clothianidin, and thiamethoxam) and proposed timelines for the final re-evaluation decisions.